Verified· 3 sources

Baxiva AG

Summary

About the company

Baxiva AG develops glycoconjugate vaccines for the prevention of bacterial infections. Its platform chemically links serotype-specific bacterial polysaccharides to virus-like particles (VLPs) to generate immunogenic, multivalent vaccine candidates against Gram-negative pathogens such as Escherichia coli.

AI-generated

Offering

Products & services

Industry:Pharmaceutical Industry

Outbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub

Baxiva AG

About the company

Products & services

Looking for direct email addresses and phone numbers?

Baxiva AG

About the company

Products & services

Looking for direct email addresses and phone numbers?

Mentions & media

No knowledge articles yet

Baxiva AG in comparison

Industry comparisons are coming soon

Similar companies